Clinical Trial Update: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA [Phase 2]

View source ↗

Summary

A phase 2 trial of Tusamitamab ravtansine in non-small cell lung cancer patients with low to moderate CEACAM5 expression and high circulating CEA was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tusamitamab Ravtansine (Tusamitamab Ravtansine)

Snippet

Sponsor: Sanofi | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-03-25